SarcopeniaNCT07815158
Multi-Component Nutrition, Intrinsic Capacity, and Physical Function in Older Adults
A study testing Multi-Component Nutritional Formula in people with Sarcopenia and Intrinsic Capacity, run by National Yang Ming Chiao Tung University at 1 site in Taiwan.
Trial summary
To evaluate the effects of a 12-week multi-component nutritional formula on World Health Organization (WHO) Integrated Care for Older People (ICOPE) intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Sarcopenia, Intrinsic Capacity
- What is being tested?
- Multi-Component Nutritional Formula
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteTaiwan
- Study dates
- 31 Aug 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Age 65 years and older.
- Intact consciousness and cognitive ability to understand and cooperate with the study protocol.
- Capable of oral ingestion and self-administration of the study formula/placebo.
- Meets at least one of the following priority recruitment criteria:
- Screened positive for decline in at least one WHO ICOPE intrinsic capacity domain (locomotion, vitality, cognition, psychology, vision, or hearing).
- Sarcopenia risk based on AWGS 2019 criteria: low handgrip strength (<28 kg for men; <18 kg for women), slow 6-meter gait speed (<1.0 m/s), or Short Physical Performance Battery (SPPB) score ≤ 9.
- Ability to attend scheduled hospital outpatient visits at baseline (Week 0) and Week 12.
- Willing and able to provide written informed consent.
Who cannot join
- Severe hepatic impairment (GPT/ALT > 3 times the upper limit of normal, or a confirmed diagnosis of liver cirrhosis).
- Severe renal impairment (serum creatinine ≥ 2.0 mg/dL, eGFR < 30 mL/min/1.73m², or a confirmed history of renal failure, chronic kidney disease, uremia, or dialysis).
- Confirmed clinical diagnosis of dementia.
- Active malignant neoplasms currently undergoing active oncological therapy (chemotherapy, radiotherapy, or targeted therapy).
- Current use of oral anticoagulant medication (Warfarin) due to potential interactions with fish oil and vitamin K2.
- Known allergy or hypersensitivity to any ingredient of the study product (dairy, soy, or fish sources).
- High-dose supplementation with whey protein, fish oil, or botanical extracts within the past 3 months.
- Presence of an active middle-ear implant or cochlear implant (to eliminate confounding factors during hearing assessments).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effects of a Multi-Component Nutritional Formula on WHO ICOPE Intrinsic Capacity Domains, Physical Function, and Metabolic Biomarkers in Community-Dwelling Older Adults: A Double-Blind Randomized Controlled Trial
To evaluate the effects of a 12-week multi-component nutritional formula on World Health Organization (WHO) Integrated Care for Older People (ICOPE) intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Besides, the investigators use standardized ICOPE Step 2 assessments, functional capacity scales, and metabolic biomarkers (including GDF-15, HOMA-IR, TyG index, LAP, and FIB-4) as outcome measures to validate whether the multi-component nutritional supplement could improve intrinsic capacity and health in older adults.
Read the detailed description
With aging, physiological functions and intrinsic capacity across multiple domains decline, leading to increased risks of sarcopenia, frailty, and metabolic dysfunction. The World Health Organization (WHO) introduced the Integrated Care for Older People (ICOPE) framework - covering locomotion, vitality, cognition, psychology, vision, and hearing - to promote healthy aging. This double-blind randomized controlled trial evaluates whether a 12-week intervention using an 18-component multi-component nutritional formula can improve ICOPE intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Through this trial, investigators aim to establish clinical evidence for nutritional strategies in managing age-related functional and metabolic declines.
- Conditions
- Sarcopenia, Intrinsic Capacity
- Being tested
- Multi-Component Nutritional Formula, matched placebo
- Keywords
- Sarcopenia, frailty, intrinsic capacity, Physical Function, Metabolic Biomarkers, Multi-Component Nutritional Supplement
- Medical subject headings
- Sarcopenia, Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-Component Nutritional FormulaDietary supplement
Daily oral consumption of the multi-component nutritional powder dissolved in warm water for 12 weeks. The formula contains muscle-anabolic proteins (whey protein, yeast protein, leucine), bone-supportive nutrients (MBP, coral calcium, vitamins D3/K2), and bioactive compounds (mulberry leaf extract, astragalus, grape seed extract, phosphatidylserine, fish oil, and lutein).
matched placeboDietary supplement
Daily oral consumption of the matched placebo powder dissolved in warm water for 12 weeks. The placebo is calorie-matched (within 10% caloric difference) but contains no active proteins, free amino acids, calcium/vitamin D3/K2 supplements, fish oil, or botanical extracts.
| Study group | Role | What they receive |
|---|---|---|
| Experimental: Multi-Component Nutritional Formula Group | Experimental | Participants in this group receive the active 18-component multi-component nutritional formula daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity. Receives: Dietary Supplement: Multi-Component Nutritional Formula |
| Placebo Comparator: Matched Placebo Group | Placebo comparator | Participants in this group receive an appearance-, flavor-, and taste-matched placebo powder daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity. Receives: Dietary Supplement: matched placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Locomotion Measured by Short Physical Performance Battery (SPPB)
Assessed by the Short Physical Performance Battery (SPPB), covering balance, chair stand, and gait speed. Scores range from 0 to 12, where higher scores indicate better lower-extremity physical function.
Measured: Baseline, Week 12
Change in 6-Meter Gait Speed
Measured by the 6-meter gait speed test in meters per second (m/s). Higher speed indicates better physical mobility
Measured: Baseline, Week 12
Change in Handgrip Strength
Measured in kilograms (kg) using a handheld dynamometer on the dominant hand (maximum of two trials). Higher values indicate greater muscle strength.
Measured: Baseline, Week 12
Change in Nutritional Status by MNA-SF
Assessed by the Mini Nutritional Assessment-Short Form (MNA-SF). Scores range from 0 to 14, where scores ≤11 indicate malnutrition risk and higher scores represent better nutritional status
Measured: Baseline, Week 12
Change in Body Weight
Measured in kilograms (kg) under fasting conditions.
Measured: Baseline, Week 12
Change in Calf Circumference
Measured in centimeters (cm) at the widest part of the calf. Higher values indicate greater muscle mass reserve.
Measured: Baseline, Week 12
Change in Cognitive Function by MoCA
Assessed by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores reflecting better global cognitive performance.
Measured: Baseline, Week 12
Change in Depressive Symptoms by GDS-5
Assessed by the 5-item Geriatric Depression Scale (GDS-5). Scores range from 0 to 5, where higher scores indicate greater depressive symptoms (scores ≥2 suggest depression risk).
Measured: Baseline, Week 12
Change in Visual Impairment Status
Evaluated based on WHO ICOPE Step 2 vision assessment criteria (classified as visual impairment: Yes or No).
Measured: Baseline, Week 12
Change in Hearing Impairment Status
Evaluated using the whisper voice test based on WHO ICOPE Step 2 criteria (classified as hearing impairment: Yes or No).
Measured: Baseline, Week 12
Secondary outcomes (16)
Change in Basic Activities of Daily Living by Barthel Index
Scores range from 0 to 100, where higher scores indicate greater independence in physical functioning and personal care.
Measured: Baseline, Week 12
Change in Instrumental Activities of Daily Living by Lawton IADL Scale
Assessed using the Lawton Instrumental Activities of Daily Living (IADL) Scale, with scores ranging from 0 to 8, where higher scores indicate better ability to perform instrumental activities of daily living.
Measured: Baseline, Week 12
Change in Frailty Status by Fried CHS Phenotype
Evaluated using the Fried Cardiovascular Health Study (CHS) criteria (0 to 5 criteria), categorizing participants as robust (0), pre-frail (1-2), or frail (3-5).
Measured: Baseline, Week 12
Change in Clinical Frailty Scale (CFS)
Measured using the Clinical Frailty Scale (CFS), with scores ranging from 1 to 9, where higher scores indicate greater frailty and a worse outcome.
Measured: Baseline, Week 12
Change in Quality of Life by SF-36 Health Survey
Assessed by the Short Form 36 (SF-36) questionnaire, evaluating physical and mental health component summary scores (scores 0-100, higher scores reflect better quality of life).
Measured: Baseline, Week 12
Change in Skeletal Muscle Mass Index by Bioelectrical Impedance Analysis (BIA)
Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Skeletal Muscle Mass Index (SMI) is expressed in kg/m². Higher SMI values indicate greater skeletal muscle mass relative to height and a better outcome.
Measured: Baseline, Week 12
Change in Visceral Fat Area by Bioelectrical Impedance Analysis
Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Visceral Fat Area (VFA) is expressed in cm². Higher VFA values indicate greater visceral adiposity and a worse outcome.
Measured: Baseline, Week 12
Change in Body Fat Percentage by Bioelectrical Impedance Analysis
Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Body Fat Percentage is expressed as a percentage (%). Higher body fat percentage indicates a greater proportion of body fat and a worse outcome.
Measured: Baseline, Week 12
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
calculated by Homeostatic Model Assessment for Insulin Resistance, HOMA-IR
Measured: Baseline, Week 12
Change in Triglyceride-Glucose (TyG) Index
calculated by Triglyceride-Glucose Index, TyG index. Higher values indicate greater metabolic and insulin resistance risk.
Measured: Baseline, Week 12
Change in Lipid Accumulation Product (LAP)
calculated by Lipid Accumulation Product, LAP. Reflects visceral adiposity.
Measured: Baseline, Week 12
Change in Serum Growth Differentiation Factor-15 (GDF-15)
measured by serum Growth Differentiation Factor-15, GDF-15, as a circulating biomarker of biological aging and mitochondrial stress.
Measured: Baseline, Week 12
Change in Fibrosis-4 (FIB-4) Index
calculated by Fibrosis-4 Index, FIB-4. Used to estimate hepatic steatosis-associated fibrosis risk.
Measured: Baseline, Week 12
Change in Glycated Hemoglobin (HbA1c)
measured by Glycated Hemoglobin, HbA1c
Measured: Baseline, Week 12
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Measured in mg/L as a circulating marker of systemic low-grade inflammation.
Measured: Baseline, Week 12
Change in Serum 25-Hydroxyvitamin D [25(OH)D]
Measured in ng/mL to reflect nutritional vitamin D status
Measured: Baseline, Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start31 Aug 2026 (estimated)
- Primary completion15 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Seventy community-dwelling or outpatient older adults (≥65 years, with ≥1 ICOPE domain impairment) will be randomized 1:1 to Nutritional Supplement A or matched placebo for 12 weeks. ICOPE Step 2 standardized assessment covers all six domains. Layer 2 outcomes include IADL (Lawton), Barthel Index, CHS Frailty Phenotype, CFS, SF-36, and body composition (InBody BIA + DXA). Layer 3 metabolic biomarkers are assessed at baseline and Week 12.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Yang Ming Chiao Tung University
- Sponsor type
- University, hospital or other
- Collaborators
- Kaohsiung Veterans General Hospital., Taiwan Association of Integrated Care
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07815158
- Sponsor's protocol ID
- 26-CT7-26(260624-2)
- Status last verified
- Aug 2026
- First submitted
- 21 Aug 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of a Multi-Component Nutritional Formula on WHO ICOPE Intrinsic Capacity Domains, Physical Function, and Metabolic Biomarkers in Community-Dwelling Older Adults: A Double-Blind Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07815158
- Acronym / sponsor ID
- 26-CT7-26(260624-2)
- Conditions
- Sarcopenia, Intrinsic Capacity
- Keywords
- Sarcopenia, frailty, intrinsic capacity, Physical Function, Metabolic Biomarkers, Multi-Component Nutritional Supplement
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- National Yang Ming Chiao Tung UniversityUniversity, hospital or other
- Collaborators
- Kaohsiung Veterans General Hospital., Taiwan Association of Integrated Care
- Study start
- 31 Aug 2026 (estimated)
- Primary completion
- 15 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 11 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the effects of a 12-week multi-component nutritional formula on World Health Organization (WHO) Integrated Care for Older People (ICOPE) intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Besides, the investigators use standardized ICOPE Step 2 assessments, functional capacity scales, and metabolic biomarkers (including GDF-15, HOMA-IR, TyG index, LAP, and FIB-4) as outcome measures to validate whether the multi-component nutritional supplement could improve intrinsic capacity and health in older adults.
Detailed description
With aging, physiological functions and intrinsic capacity across multiple domains decline, leading to increased risks of sarcopenia, frailty, and metabolic dysfunction. The World Health Organization (WHO) introduced the Integrated Care for Older People (ICOPE) framework - covering locomotion, vitality, cognition, psychology, vision, and hearing - to promote healthy aging. This double-blind randomized controlled trial evaluates whether a 12-week intervention using an 18-component multi-component nutritional formula can improve ICOPE intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Through this trial, investigators aim to establish clinical evidence for nutritional strategies in managing age-related functional and metabolic declines.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Seventy community-dwelling or outpatient older adults (≥65 years, with ≥1 ICOPE domain impairment) will be randomized 1:1 to Nutritional Supplement A or matched placebo for 12 weeks. ICOPE Step 2 standardized assessment covers all six domains. Layer 2 outcomes include IADL (Lawton), Barthel Index, CHS Frailty Phenotype, CFS, SF-36, and body composition (InBody BIA + DXA). Layer 3 metabolic biomarkers are assessed at baseline and Week 12.
| Arm | Type | Receives |
|---|---|---|
| Experimental: Multi-Component Nutritional Formula Group | Experimental | Dietary Supplement: Multi-Component Nutritional FormulaParticipants in this group receive the active 18-component multi-component nutritional formula daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity. |
| Placebo Comparator: Matched Placebo Group | Placebo comparator | Dietary Supplement: matched placeboParticipants in this group receive an appearance-, flavor-, and taste-matched placebo powder daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (8 listed)
- Age 65 years and older.
- Intact consciousness and cognitive ability to understand and cooperate with the study protocol.
- Capable of oral ingestion and self-administration of the study formula/placebo.
- Meets at least one of the following priority recruitment criteria:
- Ability to attend scheduled hospital outpatient visits at baseline (Week 0) and Week 12.
Key exclusion criteria (8 listed)
- Severe hepatic impairment (GPT/ALT > 3 times the upper limit of normal, or a confirmed diagnosis of liver cirrhosis).
- Severe renal impairment (serum creatinine ≥ 2.0 mg/dL, eGFR < 30 mL/min/1.73m², or a confirmed history of renal failure, chronic kidney disease, uremia, or dialysis).
- Confirmed clinical diagnosis of dementia.
- Active malignant neoplasms currently undergoing active oncological therapy (chemotherapy, radiotherapy, or targeted therapy).
- Current use of oral anticoagulant medication (Warfarin) due to potential interactions with fish oil and vitamin K2.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-Component Nutritional FormulaDaily oral consumption of the multi-component nutritional powder dissolved in warm water for 12 weeks. The formula contains muscle-anabolic proteins (whey protein, yeast protein, leucine), bone-supportive nutrients (MBP, coral calcium, vitamins D3/K2), and bioactive compounds (mulberry leaf extract, astragalus, grape seed extract, phosphatidylserine, fish oil, and lutein). | Dietary supplement | Experimental: Multi-Component Nutritional Formula Group |
| matched placeboDaily oral consumption of the matched placebo powder dissolved in warm water for 12 weeks. The placebo is calorie-matched (within 10% caloric difference) but contains no active proteins, free amino acids, calcium/vitamin D3/K2 supplements, fish oil, or botanical extracts. | Dietary supplement | Placebo Comparator: Matched Placebo Group |
Primary outcome
Change in Locomotion Measured by Short Physical Performance Battery (SPPB)
Time frame: Baseline, Week 12
Assessed by the Short Physical Performance Battery (SPPB), covering balance, chair stand, and gait speed. Scores range from 0 to 12, where higher scores indicate better lower-extremity physical function.
Change in 6-Meter Gait Speed
Time frame: Baseline, Week 12
Measured by the 6-meter gait speed test in meters per second (m/s). Higher speed indicates better physical mobility
Change in Handgrip Strength
Time frame: Baseline, Week 12
Measured in kilograms (kg) using a handheld dynamometer on the dominant hand (maximum of two trials). Higher values indicate greater muscle strength.
Change in Nutritional Status by MNA-SF
Time frame: Baseline, Week 12
Assessed by the Mini Nutritional Assessment-Short Form (MNA-SF). Scores range from 0 to 14, where scores ≤11 indicate malnutrition risk and higher scores represent better nutritional status
Change in Body Weight
Time frame: Baseline, Week 12
Measured in kilograms (kg) under fasting conditions.
Change in Calf Circumference
Time frame: Baseline, Week 12
Measured in centimeters (cm) at the widest part of the calf. Higher values indicate greater muscle mass reserve.
Change in Cognitive Function by MoCA
Time frame: Baseline, Week 12
Assessed by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores reflecting better global cognitive performance.
Change in Depressive Symptoms by GDS-5
Time frame: Baseline, Week 12
Assessed by the 5-item Geriatric Depression Scale (GDS-5). Scores range from 0 to 5, where higher scores indicate greater depressive symptoms (scores ≥2 suggest depression risk).
Change in Visual Impairment Status
Time frame: Baseline, Week 12
Evaluated based on WHO ICOPE Step 2 vision assessment criteria (classified as visual impairment: Yes or No).
Change in Hearing Impairment Status
Time frame: Baseline, Week 12
Evaluated using the whisper voice test based on WHO ICOPE Step 2 criteria (classified as hearing impairment: Yes or No).
16 secondary outcomes
Change in Basic Activities of Daily Living by Barthel Index
Time frame: Baseline, Week 12
Change in Instrumental Activities of Daily Living by Lawton IADL Scale
Time frame: Baseline, Week 12
Change in Frailty Status by Fried CHS Phenotype
Time frame: Baseline, Week 12
Change in Clinical Frailty Scale (CFS)
Time frame: Baseline, Week 12
Change in Quality of Life by SF-36 Health Survey
Time frame: Baseline, Week 12
Change in Skeletal Muscle Mass Index by Bioelectrical Impedance Analysis (BIA)
Time frame: Baseline, Week 12
Change in Visceral Fat Area by Bioelectrical Impedance Analysis
Time frame: Baseline, Week 12
Change in Body Fat Percentage by Bioelectrical Impedance Analysis
Time frame: Baseline, Week 12
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time frame: Baseline, Week 12
Change in Triglyceride-Glucose (TyG) Index
Time frame: Baseline, Week 12
Change in Lipid Accumulation Product (LAP)
Time frame: Baseline, Week 12
Change in Serum Growth Differentiation Factor-15 (GDF-15)
Time frame: Baseline, Week 12
Change in Fibrosis-4 (FIB-4) Index
Time frame: Baseline, Week 12
Change in Glycated Hemoglobin (HbA1c)
Time frame: Baseline, Week 12
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Time frame: Baseline, Week 12
Change in Serum 25-Hydroxyvitamin D [25(OH)D]
Time frame: Baseline, Week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Sarcopenia
Active, not recruitingObservational study
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
Primary Sjögren Syndrome, Sarcopenia
Not yet recruiting
PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty
Frailty, Sarcopenia
Recruiting
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
Recruiting
Effects of a Community-based Multicomponent Physical Exercise Program on Physical Function, Frailty, and Sarcopenia in Older Adults From the Municipality of Santoña: a Quasi-experimental Study.
Frailty/Sarcopenia, Frailty in Older Adults
Not yet recruiting
Creatine and Muscle Health in Madrid's Walking Footballers.
Muscle Adaptation, Body Composition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multi-Component Nutritional Formula in people with Sarcopenia and Intrinsic Capacity, run by National Yang Ming Chiao Tung University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chih-Kuang Liang (07-3422121 ext. 72091, Ck.vghks@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Locomotion Measured by Short Physical Performance Battery (SPPB) (time frame: Baseline, Week 12). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.